These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27230697)

  • 21. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of istradefylline in the Parkinson's disease armamentarium.
    Müller T
    Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa treatment and dendritic spine pathology.
    Nishijima H; Ueno T; Funamizu Y; Ueno S; Tomiyama M
    Mov Disord; 2018 Jul; 33(6):877-888. PubMed ID: 28880414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?].
    Jost WH; Tönges L
    Fortschr Neurol Psychiatr; 2022 Dec; 90(12):565-570. PubMed ID: 35226930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Adenosine A
    Zheng J; Zhang X; Zhen X
    ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacotherapy of Parkinson's disease: progress or regress?].
    Pytka K; Zygmunt M; Filipek B
    Postepy Hig Med Dosw (Online); 2013 Jul; 67():700-8. PubMed ID: 24018435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Milestones in Parkinson's disease therapeutics.
    Rascol O; Lozano A; Stern M; Poewe W
    Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin 5-HT
    Pinna A; Parekh P; Morelli M
    Neuropharmacology; 2023 Mar; 226():109411. PubMed ID: 36608814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
    Pilleri M; Antonini A
    Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    Duty S
    CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatment and future prospects of dopa-induced dyskinesias.
    Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
    Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.